PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “TOXICOLOGY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources

Setting standards of practice in therapeutic drug monitoring and clinical toxicology: a North American view.

Standards for therapeutic drug monitoring (TDM) must address the factors required for a valid TDM result. These are that the test be ordered with an appropriate indication, samples be obtained at the appropriate time, analysis be precise and accurate, and the result be interpreted and used correctly. General indications for ordering drug concentrations are to assess patient compliance, lack of response, adverse effects, initial or new baseline concentration after steady state has been achieved, and drug interactions. In establishing standards for clinical toxicology testing, the following points need to be considered: relatively few drugs will be involved in the majority of overdoses in a given location, the majority of drug overdoses and poisonings are treated symptomatically and supportively, and there are a relatively small number of drugs the testing of which may provide useful information in the emergency setting. An effective toxicology screen can be designed by first developing a list of candidate drugs that have antidotes, require specific treatment, are frequently encountered, or have a delayed onset of toxicity. Once such a list is in hand, it can be further evaluated to determine whether qualitative or quantitative testing is most appropriate and if rapid, convenient methods of analysis are available.

Animals↗

Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology?

This paper reviews the different attempts made to develop efficient LC-MS techniques for systematic toxicologic analysis, or general unknown screening (GUS) of drugs and toxic compounds. Only particle beam interfaces are compatible with electron ionization, but they mainly cover the same range of compounds as GC-MS, i.e. nonpolar, thermally stable molecules. Using the more used electrospray sources, several approaches were used: tandem-mass spectrometry (MS/MS); MS/MS with data-dependent or information-dependent acquisition (DDA or IDA); and single mass spectrometry with in-source collision induced dissociation (CID). The MS/MS strategy is not really compatible with a GUS procedure, as it requires selecting a limited number of ions in the first step, before fragmenting them. DDA or IDA are auto-adaptive MS/MS product-ion scan modes where the m/z ratios the intensity of which is above a given threshold are selected at each unit time. Preliminary studies showed their potential for GUS, but it will probably be necessary to improve the detection of signals of toxicologic interest among background noise. This is also the case for single-MS techniques with in-source CID. Such methods have been proposed by several teams, who demonstrated their repeatability and reproducibility, at least on a same type of instrument and on an intralaboratory basis. Optimized extraction procedures are necessary to recover polar and even hydrophilic drugs, which are those supposed to be detectable by LC-ES-MS and not GC-MS, and such nonselective extraction may be responsible for high chemical noise. Chromatographic conditions and the resulting separation, resolution and signal-to-noise ratio are also probably important determinants of the efficiency of such procedures. Preliminary results using an optimized LC-ES-MS GUS technique showed that it is probably as efficient as GC-MS or HPLC-DAD for the detection of drugs and toxicants in clinical serum samples and that it is complementary to both these techniques.

Animals↗

Scoring and performance of analysis and interpretation of toxicologic cases assessed by external quality assurance.

Quantitative analysis of toxicology cases requires knowledgeable interpretation. We describe a scoring scheme that integrates analytical and interpretive performance for such cases using a reward/penalty scoring scheme. This scheme has been validated on cases circulated over the previous 5 years to volunteer participants in the UKNEQAS for Drug Assays Scheme. We have been able to identify a subset of poorly performing laboratories that should desist from toxicologic analysis and interpretation.

Humans↗

Postmortem drug analysis: analytical and toxicological aspects.

Publications focusing on the analysis of postmortem specimens for the presence of drugs were reviewed with particular reference to systematic toxicological analysis. Specimens included blood, liver, other solid specimens, and fly larvae. Extraction techniques published during the past 10 years most commonly used traditional solvent extraction techniques. High-performance liquid chromatography coupled to multichannel wavelength detection was most commonly used, which would easily lend itself to liquid chromatography-mass spectrometry. There were few practical differences in the assays validated for a range of postmortem specimens to those in other forms of forensic toxicology, unless substantially decomposed tissue was used. When putrefied specimens were analyzed, a back-extraction or other form of specimen cleanup was recommended to reduce interfering substances. Many immunoassays designed for urine have been adapted for use in blood and tissue homogenates. Immunoassays designed for blood analysis, however, are likely to have more useful cutoff values than immunoassays optimized for urine testing. Postmortem specimens provide less stability for a number of drugs than other types of specimens. This is particularly a problem for cocaine, heroin, and some antidepressants, antipsychotics, and benzodiazepines. A number of artifacts occur postmortem, which affects the concentration of drug in specimens. This includes postmortem redistribution for drugs with a high tissue concentration relative to blood. Consequently, the likely extent of any change in concentration is relevant to the interpretation of doses and drug effects.

Animals↗

Clinical toxicologic implications of ethylene glycol and glycolic acid poisoning.

Metabolic pathways have been elucidated for various chemical and solvent exposures in humans. Clinical laboratory analyses in most chemical and solvent exposures are directed toward identification and quantitation of unchanged substance in serum or whole blood. For example, most laboratories routinely screen for unchanged ethylene glycol in suspected poisonings and quantitate ethylene glycol in positive cases even though toxicity from ethylene glycol exposure (including central nervous system depression, acute renal failure, and elevated anion gap metabolic acidosis) is primarily caused by one metabolite-glycolic acid. One objective of this manuscript is to describe the authors' clinical experience with glycolic acid analysis in ethylene glycol human poisonings. Recommended clinical laboratory tests for small hospitals and toxicology reference laboratories are presented to rule out or confirm ethylene glycol exposure. Another concern with laboratory support in ethylene glycol poisoning is correct identification of ethylene glycol because analysis of this substance is often problematic. In one case laboratories incorrectly identified an organic acid from an inherited metabolic disease as ethylene glycol, and in another case the intentional ethylene glycol poisoning of an infant was determined to be the results of an endogenous organic acid. The most robust analytical methods for determining ethylene glycol and glycolic acid are chromatographic methods. Ideally, screening methods for ethylene glycol should be confirmed by another method based on a different principle of analysis or include simultaneous metabolite analysis (glycolic acid). In centers where several ethylene glycol cases present annually, toxicology laboratories supporting these centers should incorporate glycolic acid monitoring in their ethylene glycol screening programs and include analysis of both ethylene glycol and glycolic acid during treatment (hemodialysis) in all confirmed poisonings. Measurement of glycolic acid provides important diagnostic and prognostic information that one cannot correlate with the amount of ethylene glycol in serum or whole blood.

Aged↗

Toxicology: assessing the hazard.

Some of the fundamentals of toxicology that are used by the toxicologist in assessing the toxic properties of compounds have been discussed. It is easy to see that a large amount of keen professional judgment must enter into the toxicologist's decisions. It is not a job that can be done by an amateur, even though some well meaning lay and political associates may believe they are capable of doing so. The toxicologist's job is not finished when he has determined the toxicological properties of a compound. He then has to assess the hazard of the compound, an infinitely more complex and complicated task. In the end, as stated by Dr. Mrak, "There are no harmless substances, there are only harmless ways of using substances" (quoted in Reference 1, p. 11).

Animals↗

Regulatory toxicology perspectives on the development of botanical drug products in the United States.

Toxicological studies constitute an essential part of the effort in developing a botanical supplement into a drug product. The US Food and Drug Administration recently published a draft guidance and established a special botanical review team to assist academic and industry sponsors to manage this and other regulatory considerations related to this unique group of drug products. In this article, the current state of regulatory viewpoints on issues related to requirements and recommendations of various types of nonclinical toxicity studies in support of advanced phases clinical trials and filing a New Drug Application of a botanical are discussed. Topics include nonclinical pharmacology/toxicology view of previous human experience and initial clinical trial, regulatory perspectives on acute toxicity studies, chronic toxicity studies, mutagenicity studies, reproductive toxicity studies, and carcinogenicity studies on botanicals. Certain regulatory review-related issues are also presented. It is anticipated that through a proactive 2-way communication between the Agency and the sponsor, toxicological development of botanical drug product can be significantly facilitated.

Animals↗

A 10-year review of the Teaching Hospital-Based National Drug and Toxicology Information Service in Zimbabwe.

The drug and toxicology information service (DaTIS), at the Department of Pharmacy, University of Zimbabwe Medical School, was set up in 1979. The service is mainly delivered to health professionals and to a lesser extent to the community. The DaTIS is designed to help solve complex clinical questions. Most of the requests are made by telephone. Urgent questions may be initially answered by telephone, or a phone call can be returned after in-depth documentation. A complete answer with references may be written and sent to the enquirer. Written non-urgent questions may be sent a few days to a few weeks later. This report is based on a systematic review of records compiled over the period between January 1983 and July 1988. Of the 1,000 requests received and recorded during the period under consideration, approximately 750 (75%) were on drug information and 250 (25%) were on poisoning or toxicological information. The most common causes of poisonings were due to organophosphate pesticides and fertilizers, Elephant's Ear, Amanita Phalloides mushroom, medicines affecting the central nervous system, e.g. tranquilizers, psychotropics, and chemicals, especially those used for hair relaxing. Only the first three causes of poisoning are discussed in detail. Most of the queries relating to poisoning, especially those received during the night, were not recorded. These results confirm the need for an adequate number of qualified and committed manpower to share the work-load in DaTIS as well as in teaching, research and in the continuous health education of the community. The results obtained by DaTIS and a recent survey (14) indicate that Zimbabwe has a big poisoning problem, especially with regard to pesticides and treatments recommended by the traditional healer. Education and information dissemination to health professionals, workers and the general public on the toxic agents concerned are vital and, although steps have been taken in this direction, much still remains to be done. Moreover, the report confirms the importance of the service to health professionals and the community in the country and the SADCC (Southern African Development Conference Committee) region as a whole.

Drug Information Services↗

Issues in qualitative and quantitative risk analysis for developmental toxicology.

The qualitative and quantitative evaluation of risk in developmental toxicology has been discussed in several recent publications. A number of issues still are to be resolved in this area. The qualitative evaluation and interpretation of end points in developmental toxicology depends on an understanding of the biological events leading to the end points observed, the relationships among end points, and their relationship to dose and to maternal toxicity. The interpretation of these end points is also affected by the statistical power of the experiments used for detecting the various end points observed. The quantitative risk assessment attempts to estimate human risk for developmental toxicity as a function of dose. The current approach is to apply safety (uncertainty) factors to the no observed effect level (NOEL). An alternative presented and discussed here is to model the experimental data and apply a safety factor to an estimated risk level to achieve an "acceptable" level of risk. In cases where the dose-response curves upward, this approach provides a conservative estimate of risk. This procedure does not preclude the existence of a threshold dose. More research is needed to develop appropriate dose-response models that can provide better estimates for low-dose extrapolation of developmental effects.

Animals↗

Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research.

Genetically engineered mice that either over-express a foreign gene (transgenic) or in which the activity of a specific gene has been removed ("knock-out") or replaced ("knock-in") will be used increasingly to investigate molecular mechanisms of disease, to evaluate innovative therapeutic targets, and to screen novel agents for efficacy and/or toxicity. Recent innovations of relevance to toxicologic researchers include the construction of genetically engineered mice with (1) multiple engineered genes, (2) mutations that can be induced at specific sites and times throughout life, and (3) the substitution of human genes for their mouse counterparts ("humanized" mice) to allow in vivo investigation of xenobiotic toxicity. Contemporary applications of genetically engineered mice in toxicology include basic mechanistic research exploiting newly engineered mouse lines as well as applied screening for genotoxicity and carcinogenicity using commercially available animals. Many caveats must be considered when interpreting genetically engineered mice-derived toxicity data, the chief of which will be the extent to which the model's phenotype has been fully characterized, the type and incidence of background lesions for the given mouse strain and engineered gene, and the possibility of misinterpreting the presence or absence of a phenotype due to compensatory physiologic processes that mask the outcome produced by the engineering event. Toxicity data acquired using genetically engineered mice currently supplements and in time likely will supplant those gathered using the present "gold standard" bioassays, as genetically engineered mice typically develop more lesions after a shorter latency period than do age- and strain-matched, wild-type mice.

Animals↗

Toxicology comes of age.

This paper contains recollections of some of the people and events that influenced the development of toxicology as an academic discipline. It also describes my experiences in pharmacology at the University of Chicago and the University of Kansas Medical Center and concludes with speculation concerning the future of toxicology. Moderation in all things/Ne quid nimis. --Terence in Andria

Certification↗

The nomenclature of cell death: recommendations of an ad hoc Committee of the Society of Toxicologic Pathologists.

The last several years have seen considerable confusion regarding the terms "apoptosis" and "necrosis" in pathology. This situation prompted the Society of Toxicologic Pathologists to charter the Committee on the Nomenclature of Cell Death, which was charged with making recommendations about the use of the terms "apoptosis" and "necrosis" in toxicity studies. The Committee recommends use of the term "necrosis" to describe findings comprising dead cells in histological sections, regardless of the pathway by which the cells died. The modifiers "apoptotic" and "oncotic" or "mixed apoptotic and oncotic" are recommended to specify the predominant morphological cell death pathway or pathways, when appropriate. Other standard modifiers, indicating the lesion distribution and severity, may also be used in conjunction with these. "Individual cell necrosis" (also known as "single cell necrosis") may be either of the apoptotic, oncotic, or mixed types. In many cases, more traditional terms such as "coagulation necrosis" may be used to convey a meaning similar to oncotic necrosis. It is important that pathologists use terms that accurately and concisely convey the level of information appropriate to the study's needs. Furthermore, toxicologic pathologists should actively help to disseminate these recommendations to other biologists and to regulatory authorities.

Animals↗

The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.

Biotechnology-derived pharmaceuticals, or biopharmaceuticals, represent a special class of complex, high molecular weight products, such as monoclonal antibodies, recombinant proteins, and nucleic acids. With these compounds, it is not appropriate to follow conventional safety testing programs, and the preclinical "package" for each biopharmaceutical needs to be individually designed. In addition to standard histopathology, the use of molecular pathology techniques is often required either in conventional animal studies or in in vitro tests. In this review, the safety evaluation of biopharmaceuticals is discussed from the perspective of the toxicologic pathologist, and appropriate examples are given of the use of molecular pathology procedures. Examples include the use of in situ hybridization to localize gene therapy vectors, the assessment of vector integration into genomic DNA by the polymerase chain reaction (PCR), and the use of immunohistochemistry to evaluate the potential cross-reactivity of monoclonal antibodies. In situ PCR techniques may allow for confirmation of the germ cell localization of nucleic acids and may therefore facilitate the risk assessment of germline transmission. Increased involvement with biopharmaceuticals will present challenging opportunities for the toxicologic pathologist and will allow for much greater use of molecular techniques, which have a critical role in the preclinical development of these compounds.

Animals↗

In vitro toxicity: mechanisms, alternatives and validation - a report from the 19th annual scientific meeting of the Scandinavian Society for Cell Toxicology.

The Scandinavian Society for Cell Toxicology (SSCT) has arranged annual scientific meetings since 1983. These workshops were the forum for the Multicentre Evaluation of In Vitro Cytotoxicity (MEIC) programme. Along with the MEIC programme, which was completed in 1998, a wide range of topics relating to cytotoxicity have been discussed. The meetings have also given an opportunity for graduate students and young scientists to present their work to an international audience. At the same time, experts in the fields of in vitro toxicity have been invited as speakers. The 19th SSCT scientific meeting, which was held at Sørup Manor in Ringsted, Denmark, was no exception. The meeting consisted of four sessions: mechanisms of toxicity; environmental toxicological testing; alternatives to animal experiments; and validation of in vitro tests.

Animal Testing Alternatives↗

Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment.

Toxicological risk assessment for chemicals is still mainly based on highly standardised protocols for animal experimentation and exposure assessment. However, developments in our knowledge of general physiology, in chemicobiological interactions and in (computer-supported) modelling, have resulted in a tremendous change in our understanding of the molecular mechanisms underlying the toxicity of chemicals. This permits the development of biologically based models, in which the biokinetics as well as the toxicodynamics of compounds can be described. In this paper, the possibilities are discussed of developing systems in which the systemic (acute and chronic) toxicities of chemicals can be quantified without the heavy reliance on animal experiments. By integrating data derived from different sources, predictions of toxicity can be made. Key elements in this integrated approach are the evaluation of chemical functionalities representing structural alerts for toxic actions, the construction of biokinetic models on the basis of non-animal data (for example, tissue-blood partition coefficients, in vitro biotransformation parameters), tests or batteries of tests for determining basal cytotoxicity, and more-specific tests for evaluating tissue or organ toxicity. It is concluded that this approach is a useful tool for various steps in toxicological hazard and risk assessment, especially for those forms of toxicity for which validated in vitro and other non-animal tests have already been developed.

Animal Use Alternatives↗

Computerized information resources in toxicology and industrial health--a review.

The explosion in scientific information presents problems for toxicologists and industrial health specialists who need to respond rapidly and comprehensively to the information needs of the public, government and industry. The application of information technology enables large volumes of toxicology and industrial health information to be stored and retrieved through a variety of data-base resources. Three different categories of databases are described: dictionary, bibliographic and informational types. Examples of specific toxicology and industrial health databases within each category are given; their origin, style and content are reviewed. Specialists in the industrial health field are encouraged to improve their knowledge and literacy in the new disciplines of information technology and information science.

Computers↗

Toxicological investigations in the detection of drug-induced disease in elderly patients.

1 During 1978--1980 general toxicological investigations were performed on specimens from 211 patients (62 male, 149 female) aged 65 years and over. 2 The investigations were an important factor in establishing the diagnosis in 32 of 91 (28 male, 63 female aged 65--92 years, median 73 years) poisoned patients, most (75) of whom had deliberately taken overdoses. 3 Seventy-one patients were severely poisoned (grade 3--4 coma) and 10 died. Benzodiazepines (49%) and barbiturates (43%) were the drugs encountered most frequently, although 54% had ingested more than one pharmaceutical preparation. 4 In the survivors the depth of coma was usually greatest in patients poisoned principally with barbiturates, whilst the duration of coma and the incidence of respiratory complications were greater in those poisoned with benzodiazepines. However, there was considerable variability in the depth and duration of coma associated with a given initial plasma concentration within both groups. 5 Although general toxicological investigations can provide useful diagnostic information when poisoning is suspected in elderly patients, unequivocal interpretation of the results obtained is not always possible.

Aged↗

Clinical toxicology--past, present and future.

1. The alarming increase in the incidence of self-poisoning in Western countries in the 1950s prompted the establishment of the National Poisons Information Service in the UK and the designation of certain Regional Poisoning Treatment Centres. 2. The substances taken in acute poisoning episodes largely reflect the poisons available in the community and, in the UK at least, have changed with fashions in prescribing although psychotropic drugs and analgesics always predominate. 3. Intensive supportive care with repeat-dose oral activated charcoal and even haemoperfusion has been proved effective in acute poisoning with central nervous depressant drugs such as barbiturates even though these latter drugs are now rarely encountered in overdose. 4. Other advances in clinical toxicology include the introduction of the opiate antagonist naloxone, Fab antibody fragments for life-threatening digoxin overdosage and proven treatment for paracetamol poisoning. Analytical toxicology has also made a major contribution. 5. On the debit side, formal psychiatric assessment of patients after acute poisoning remains contentious, tricyclic antidepressants are still a major problem and there is no effective treatment for poisoning with paraquat or for paracetamol when presentation is delayed. 6. As to the future, although the 'epidemic' of serious acute poisoning of the 1960s and 70s appears to be past its peak, there will always be unusual and serious problems and the UK poisons information services must develop to make the best use of computer-based technology.

Humans↗